Filing Details

Accession Number:
0001179110-14-016206
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-11-05 17:37:08
Reporting Period:
2014-11-03
Filing Date:
2014-11-05
Accepted Time:
2014-11-05 17:37:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882095 Gilead Sciences Inc GILD Biological Products, (No Disgnostic Substances) (2836) 943047598
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1600041 Rutherford Paul Carter Gilead Sciences, Inc.
333 Lakeside Drive
Foster City CA 94404
Evp Commercial Ops No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-11-03 3,000 $40.56 35,244 No 4 M Direct
Common Stock Disposition 2014-11-03 3,000 $112.46 32,244 No 4 S Direct
Common Stock Acquisiton 2014-11-04 4,800 $0.00 37,044 No 4 M Direct
Common Stock Acquisiton 2014-11-04 2,736 $109.72 34,308 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2014-11-03 3,000 $0.00 3,000 $40.56
Common Stock Restricted Stock Unit Disposition 2014-11-04 4,800 $0.00 4,800 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
21,240 2023-02-01 No 4 M Direct
12,500 No 4 M Direct
Footnotes
  1. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
  2. The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
  3. Sale prices reported for the transactions reported here range from $112.355 to $112.52. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
  4. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  5. The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 25% every year thereafter until fully vested.